Valuation • Vir Biotechnology
VIR
Vir Biotechnology Inc., founded in 2016, is a clinical-stage biopharmaceutical company that develops innovative immunologic therapies to combat serious infectious diseases such as COVID-19 and hepatitis B. Operating within the Health Care sector, the company emphasizes leveraging advanced scientific research to meet significant unmet medical needs. Vir Biotechnology generates revenue primarily through strategic collaborations, licensing agreements, and milestone-based payments tied to its therapeutic candidates. Its business model is centered on partnering with global pharmaceutical companies and government agencies to bring novel treatments from development to commercialization. The company’s leading product candidate is VIR-7831 (sotrovimab), a monoclonal antibody that received emergency use authorization for COVID-19 treatment, forming a critical part of its portfolio. In addition, Vir is actively expanding its pipeline with candidates targeting hepatitis B and influenza, supported by collaborations with major pharma partners. Its integrated approach combines rigorous clinical development with advanced computational methods to enhance the safety and efficacy profiles of its treatments. Vir Biotechnology is led by CEO George Scangos, a veteran in the biotechnology industry with extensive experience in steering innovative drug development initiatives. Alongside him, a team of seasoned executives in research and commercialization drives the company’s strategic clinical operations and partnerships. Vir holds a competitive stature among biotech firms focused on infectious diseases, with its innovative product pipeline contributing to a market capitalization exceeding $3 billion. Strategic alliances and early successes, especially in COVID-19 therapeutics, have positioned the company as an influential player in a niche market with significant growth potential. Looking forward, Vir Biotechnology plans to advance multiple candidates through clinical trials while exploring new indications and expanding its portfolio to address broader infectious disease challenges. The company is focused on achieving key regulatory milestones, deepening its strategic partnerships, and leveraging its innovative platform to drive long-term revenue growth.
0,7
P/B
Book value of equity per share effectively indicates a firm's net asset value (total assets - total liabilities) on a per-share basis. References: Below 1: the company is trading below its equity. Equal to 1: the company is trading at the exact value of its equity. Above 1: The company is trading above its equity.
19,3
P/S
Shows how much the market values every dollar of the company's sales.
—
P/EBITDA
Shows how much the market values every dollar of the company's EBITDA.
—
P/OCF
The price-to-cash flow (P/CF) ratio is a stock valuation indicator or multiple that measures the value of a stock's price relative to its operating cash flow per share. The ratio uses operating cash flow (OCF), which adds back non-cash expenses such as depreciation and amortization to net income. P/CF is especially useful for valuing stocks that have positive cash flow but are not profitable because of large non-cash charges.
—
P/FCF
The price-to-free cash flow (P/FCF) ratio is a stock valuation indicator or multiple that measures the value of a stock's price relative to its free cash flow per share. This metric is very similar to the valuation metric of price to cash flow but is considered a more exact measure because it uses free cash flow, which subtracts capital expenditures (CAPEX) from a company's total operating cash flow, thereby reflecting the actual cash flow available to fund non-asset-related growth.
—
P/E
The price-to-earnings ratio is the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS) and is used by investors and analysts to determine the relative value of a company's shares in an apples-to-apples comparison.
14,2
BVPS
Book value per share (BVPS) takes the ratio of a firm's common equity divided by its number of shares outstanding.
—
EPS
Earnings per share (EPS) is calculated as a company's profit divided by the outstanding shares of its common stock. The resulting number serves as an indicator of a company's profitability. EPS indicates how much money a company makes for each share of its stock and is a widely used metric for estimating corporate value.
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!